Background: Cervical intraepithelial neoplasia grade 2 (CIN2) represents a controversial lesion in cervical cancer prevention. Traditionally included in the aggregate CIN2+ endpoint for reasons of diagnostic stability and statistical power, isolated CIN2 has unique biological characteristics: greater interobserver variability, a high probability of spontaneous regression and a lower risk of progression compared to CIN3. Objectives: To critically describe the epidemiology, natural history and management strategies of CIN2, integrating data from clinical and population-based studies and comparing the recommendations of the main international guidelines. Methods: A narrative review was conducted using a search of PubMed and Scopus (1990–January 2025). Prospective and retrospective studies on isolated CIN2, screening and vaccination trials with CIN2+ endpoints, biomarker research, and consensus documents (ASCCP, ESGO, GISCi, Ministry of Health, WHO) were included. Results: Clinical studies have shown a high probability of CIN2 regression (50–70% within two years, >70% in those <25 years), compared to a 10–15% risk of progression, especially in the presence of persistent HPV16. Screening trials and vaccine evaluations with CIN2+ endpoints have documented the efficacy of the HPV test and a dramatic reduction in lesions in vaccinated cohorts, which was also confirmed for isolated CIN2. The most recent guidelines have progressively adopted a risk-based approach, which allows for active surveillance in young women or those seeking to conceive, while the WHO maintains a screen-and-treat model in resource-limited countries. Conclusions: CIN2 is not a lesion to be treated automatically, but rather a paradigmatic model for personalized management. Integrating epidemiological and clinical data, supported by biomarkers, allows for reducing overtreatment without compromising oncological safety.
Background: Locally advanced cervical cancer (LACC) represents a significant challenge in oncology, requiring accurate assessment of local extent and metastatic spread. Multiparametric magnetic resonance imaging (mpMRI) has assumed a central role in the loco-regional characterization of the tumor due to its high soft-tissue resolution and the ability to integrate functional information. Objectives: In this narrative review, we explore the use of mpMRI in the diagnosis, staging, and treatment response of LACC, comparing its performance with that of PET/CT, which remains complementary for remote staging. The potential of whole-body magnetic resonance imaging (WB-MRI) and hybrid PET/MRI techniques is also analyzed, as well as the emerging applications of radiomics and artificial intelligence. The paper also discusses technical limitations, interpretative variability, and the importance of protocol standardization. The goal is to provide an updated and translational summary of imaging in LACC, with implications for clinical practice and future research. Methods: Prospective and retrospective studies, systematic reviews, and meta-analyses on adult patients with cervical cancer were included. Results: Fifty-two studies were included. MRI demonstrated a sensitivity and specificity greater than 80% for parametrial and bladder invasion, but limited sensitivity (45–60%) for lymph node disease, lower than PET/CT. Multiparametric MRI was useful in early prediction of response to chemotherapy and radiotherapy and in distinguishing residual disease from fibrosis. The integration of MRI into Image-Guided Adaptive Brachytherapy (IGABT) resulted in improved oncological outcomes and reduced toxicity. The applications of radiomics and AI demonstrated enormous potential in predicting therapeutic response and lymph node status in the MRI study, but multicenter validation is still needed. Conclusions: MRI is the cornerstone of the local–regional staging of advanced cervical cancer; it has become an essential and crucial tool in treatment planning. Its use, combined with PET/CT for lymph node assessment and metastatic disease staging, is now the standard of care. Future prospects include the use of whole-body MRI and the development of predictive models based on radiomics and artificial intelligence.
In postmenopausal women with high-grade cervical intraepithelial neoplasia (CIN3), hysterectomy is frequently performed after loop electrosurgical excision procedure (LEEP) due to the concern for residual disease or occult carcinoma. However, the decision to proceed with hysterectomy is often made without validated predictive criteria, increasing the risk of overtreatment or underdiagnosis. The aim of this study is to identify independent predictors of residual CIN2+ (CIN2, CIN3, adenocarcinoma in situ, invasive carcinoma) or invasive disease in hysterectomy specimens following LEEP in this high-risk population. Methods: We conducted a multicenter retrospective study including 154 postmenopausal women (aged 50–75) who underwent total hysterectomy within 12 months after LEEP for histologically confirmed CIN3. Data collected included human papillomavirus (HPV) genotyping (pre- and post-LEEP), endocervical curettage (ECC), cone margin status, transformation zone type, and histopathological outcomes of the hysterectomy specimen. Logistic regression and ROC curve analysis were used to assess predictive factors. Results: Residual disease (CIN2+, AIS, or carcinoma) was found in 38 patients (24.7%), including 7 cases (4.5%) of occult carcinoma. Persistent high-risk HPV post-LEEP was the strongest independent predictor (adjusted OR for HPV 16/18: 74.0; p < 0.001), followed by positive ECC (OR: 3.64; p = 0.028). Cone margin status was not independently associated. The multivariate model showed good discriminative performance (AUC = 0.860; sensitivity 67.2%, specificity 72.8%). Conclusions: Our findings suggest that persistent high-risk HPV infection and positive ECC are reliable predictors of residual or occult disease. These markers should be integrated into post-LEEP follow-up protocols to better identify candidates for hysterectomy and minimize unnecessary surgeries.
Background: Mammographic microcalcifications (MCs) are a common early radiological finding in breast cancer, but their significance in relation to molecular subtypes, particularly HER2-positive tumors, remains under investigation. Objectives: To evaluate the association between MCs and HER2 status in invasive breast cancer. Methods: A retrospective study was conducted on 185 patients treated at a breast unit between 2018 and 2023. Clinical, histological, and molecular data were analyzed. Logistic regression was used to identify independent predictors of MCs. Results: MCs were present in 27% of HER2-positive patients and 16.15% of HER2-negative patients (p < 0.001). HER2 positivity was the only significant independent predictor (OR = 5.89; 95% CI: 2.42–14.30; p < 0.001). Age, breast density, and histology were not associated. Conclusions: MCs are significantly associated with HER2 positivity and may serve as an early imaging marker of aggressive disease, supporting the integration of radiologic and molecular diagnostics.
Background: Conservative management of grade 2 cervical intraepithelial neoplasia (CIN2) is now supported by international guidelines, especially in young women or those seeking fertility. However, identifying subgroups at increased risk of progression remains a clinical priority, especially in settings with prolonged surveillance. Objectives: To evaluate the clinical evolution of CIN2 in an HPV-positive cohort followed under active surveillance for a maximum follow-up of 48 months, with particular attention to the risk of progression, persistence and regression, and associated predictors. Methods: Retrospective observational study conducted on a cohort of 237 HPV-positive women with a histological diagnosis of CIN2. Three possible clinical outcomes (progression, persistence, and regression) were analyzed. Patients underwent structured follow-up including cytology and colposcopy every 6 months, and HPV testing annually. Excisional treatment was performed only in case of progression or poor compliance. Logistic regression (univariate and multivariate) was applied to identify independent predictors of progression and regression. Results: After a maximum follow-up of 48 months. 61.3% of lesions regressed spontaneously, 13.1% persisted, and 25.5% progressed to CIN3. In multivariate analysis, high-grade cytology (ASC-H/HSIL) and HPV 16/18 infection were independently associated with a reduced likelihood of regression (OR ≈ 0.5, p < 0.01) and an increased risk of progression (OR ≈ 2.0, p < 0.05). Lesion size and age were not significant predictors. Importantly, no invasive carcinoma occurred during follow-up. Conclusions: Active surveillance for CIN2 remains a valid strategy in low-risk subgroups, but it is not universally safe. Data suggest that the combination of high-grade cytology and HPV 16/18 represents a high oncological risk profile, for which prompt treatment is indicated. Persistence beyond 36 months should be considered a cumulative risk marker, with implications for personalized follow-up and risk management. Further prospective, registry-linked studies are required to validate long-term safety and refine risk-based management strategies for CIN2.
Radical hysterectomy continues to be the standard treatment for early-stage cervical cancer. Accurate staging plays an important role in the management of cervical cancer, and preoperative imaging is indispensable to ensure appropriate stage assignment and to identify the surgical patient. Many studies have highlighted the need to consider the low-risk patient in a markedly different way from the intermediate- or high-risk patient. The aim of this study is to highlight the most urgent divergences to be addressed in low-risk early cervical cancer patients, such as reducing the radicality of the surgery, avoiding parametriectomy with tumors smaller than 2 cm, replacing bilateral lymphadenectomy with sentinel lymph node dissection, persistence of MIS instead of laparotomy, and preserving fertility. All this evidence is the result of the progress that has been made in recent decades in the early diagnosis, staging, and treatment of cervical cancer, made possible not only by the ever-increasing experience of gynecological oncologists but above all by the increasingly sophisticated imaging techniques that support the work of the clinician.